Clinical Trials
65 trialsPECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
METRO-NB2012
University of Cologne
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
SFCE METRO 01
Assistance Publique Hopitaux De Marseille
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
COLA
Brigham and Women's Hospital
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
Jonsson Comprehensive Cancer Center
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
LDMchemoCRC
HaEmek Medical Center, Israel
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Children's Oncology Group
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer
Maastricht University Medical Center
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Dana-Farber Cancer Institute
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
GOG Foundation
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
UAB0040
University of Alabama at Birmingham
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
City of Hope Medical Center
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
University of Kansas Medical Center
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
National Cancer Institute (NCI)
Protocol for Women at Increased Risk of Developing Breast Cancer
University of Kansas Medical Center
Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer
National Health Research Institutes, Taiwan
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
University of Michigan Rogel Cancer Center
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
Buddhist Tzu Chi General Hospital
Cox-2 Inhibition in Radiation-induced Oral Mucositis
UConn Health
ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
Helsinki University Central Hospital
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Fox Chase Cancer Center
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
National Cancer Institute (NCI)
Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia
National Cancer Institute (NCI)
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
Memorial Sloan Kettering Cancer Center